Wai Yuen Tong Medicine Holdings Ltd
HKEX:897
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Wai Yuen Tong Medicine Holdings Ltd
Operating Income
Wai Yuen Tong Medicine Holdings Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
W
|
Wai Yuen Tong Medicine Holdings Ltd
HKEX:897
|
Operating Income
-HK$45.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
15%
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Operating Income
-$3.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Operating Income
HK$1.8B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
18%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Operating Income
¥6.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Operating Income
HK$13.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Operating Income
-$39.2m
|
CAGR 3-Years
54%
|
CAGR 5-Years
28%
|
CAGR 10-Years
-15%
|
|
Wai Yuen Tong Medicine Holdings Ltd
Glance View
Wai Yuen Tong Medicine Holdings Ltd. is an investment holding company, which engages in the production and sale of pharmaceutical products. The company employs 1,825 full-time employees The firm operates through three segments. Production and Sale of Chinese Pharmaceutical and Health Food Products segment is mainly engaged in the manufacture, processing and retailing of traditional Chinese medicine in China and Hong Kong. Its products include Chinese medicines under the brand Wai Yuen Tong, as well as products manufactured with traditional prescriptions. Production and Sale of Western Pharmaceutical and Health Food Products segment is engaged in the processing and sales of Western pharmaceutical products and personal care products under the brands Madame Pearl’s and Pearl’s. Property Investment segment is engaged in the investment in commercial properties for rental income.
See Also
What is Wai Yuen Tong Medicine Holdings Ltd's Operating Income?
Operating Income
-45.8m
HKD
Based on the financial report for Sep 30, 2025, Wai Yuen Tong Medicine Holdings Ltd's Operating Income amounts to -45.8m HKD.
What is Wai Yuen Tong Medicine Holdings Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
15%
Over the last year, the Operating Income growth was 26%.
